SR One
Investor profile
Deals
5
distinct rounds
Companies
5
backed
Active span
2015–2025
11 yrs
Total round €
€246M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- F-Prime Capital2
- Versant Ventures2
- Abingworth LLP1
- Bayer Global Investments1
- Celgene1
- Dawn Biopharma1
- Export and Investment Fund of Denmark (EIFO)1
- GlaxoSmithKline1
- IP Group1
- Johnson & Johnson1
- Johnson & Johnson Innovation1
- Khosla Ventures1
- Longview Ventures1
- New Enterprise Associates1
- New Enterprise Associates (NEA)1
- Novo Holdings1
- Nvidia1
- OrbiMed1
- Pfizer Ventures1
- Pictet1
- Roche Venture Fund1
- Rosetta Capital1
- Sofinnova Partners1
- SV Life Sciences1
- Touchstone Innovations1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Antag Therapeutics | Denmark | 1 | €80M |
| Charm Therapeutics | UK | 1 | €68M |
| CRISPR Therapeutics | Switzerland | 1 | €58M |
| Pulmocide | UK | 1 | €28M |
| MISSION Therapeutics | UK | 1 | €11M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Antag Therapeutics | Series A | €80M | 2024-12 |
| Charm Therapeutics | Series B | €68M | 2025-09 |
| CRISPR Therapeutics | Series B | €58M | 2015-03 |
| Pulmocide | Series B | €28M | 2017-02 |
| MISSION Therapeutics | Other | €11M | 2025-10 |